daytrades april 28 pre-market, page-20

Good day for Biotech in early-middle trial progress ? (sinister cackle heard in background).

EMS/EMSOB - Phase-IIa trial for anti-malarial treatment particularly for children, has announced good results.

I like their attention to future trials and expression of a plan for eventual commercialisation.

Today however may not be a good day for this sort of thing, but worth watching.

Dicscl: I don't hold.